Total: $628.81M |
||||
Company |
Location |
Date |
Amt. (M) |
Details |
Advanced Cancer Therapeutics LLC |
Louisville, Ky. |
7/2 |
$10 |
Advanced Cancer secured $10M in investments from high net-worth individuals and institutions |
Agennix AG |
Planegg/ Munich, Germany |
7/26 |
€15 ($19.3) |
Agennix entered an agreement with shareholder dievini Hopp BioTech holding GmbH & Co. KG for a $19.3M loan at an interest rate of 6% per annum |
Biosystems International SAS |
Paris |
7/20 |
$2.7 |
Biosystems closed a $2.7M round of funding |
Calistoga Pharmaceuticals Inc. |
Seattle |
7/1 |
$40 |
Calistoga raised $40M in a Series C financing led by Quogue Capital LLC, along with Alta Partners, Amgen Ventures, Frazier Healthcare, Three Arch Partners and Latterell Venture Partners |
Calithera Biosciences Inc. |
San Francisco |
7/9 |
$40 |
Calithera raised $40M in a Series A round led by Morgenthaler Ventures, with participation from U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital |
Cara Therapeutics Inc. |
Shelton, Conn. |
7/22 |
$15 |
Cara raised $15M in a Series D round led by Rho Ventures, with participation from Alta Biopharma, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, Healthcare Private Equity, Mitsubishi International Corp. and MVM Life Science Partners |
Cerenis Therapeutics SA |
Toulouse, France |
7/27 |
€40 ($51.9) |
Cerenis raised $51.9M in a Series C round led by Fund for Strategic Investment |
CMP Therapeutics Ltd. |
London |
7/30 |
€1.5 ($1.96) |
CMP raised $1.96M through a convertible loan from Inventages Venture Capital |
Euthymics Bioscience Inc. |
Cambridge, Mass. |
7/22 |
$24 |
Euthymics raised $24M in a Series A round from Novartis Venture Fund and Venture Investors as well as Hambrecht & Quist Capital Management LLC, GBS Venture Partners and the State of Wisconsin Investment Board |
Excelimmune |
Woburn, Mass. |
7/8 |
$4.5 |
Excelimmune raised $4.5M in a new financing |
HemaQuest Pharmaceuticals Inc. |
Seattle |
7/29 |
$4 |
HemaQuest raised $4M in a Series B by Latterell Venture Partners, bringing the total to $16M; other investors were Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures |
Immune Design Corp. |
Seattle |
7/27 |
$32 |
Immune Design raised $32M in Series B funding led by ProQuest Investments and including the Column Group, Versant Ventures and Alta Partners |
InVasc Therapeutics Inc. |
Atlanta |
7/12 |
$3.15 |
InVasc raised $3.15M in an initial closing of its first institutional financing led by Trois I Investments Industriels Internationaux SA |
iPierian Inc. |
South San Francisco |
7/9 |
$22 |
iPierian raised $22M in a Series B equity financing led by new investor Google Ventures; other investors were Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital |
Kymab Ltd. |
London |
7/13 |
£20 ($30.1) |
Kymab raised $30.1M in a first round from the Wellcome Trust |
Metamark Genetics Inc. |
Cambridge, Mass. |
7/14 |
$22 |
Metamark completed a $22M Series B round |
Nitric BioTherapeutics Inc. |
Bristol, Pa. |
7/16 |
$6 |
Nitric closed a $6M financing led by inside investors |
Pacific Biosciences |
Menlo Park, Calif. |
7/15 |
$59 |
Pacific Biosciences raised $109M in a Series F financing, including a $50M investment by Gen-Probe Inc., which was disclosed in June |
Pantec Biosolutions AG |
Ruggell, Liechtenstein |
7/21 |
CHF20 ($19) |
Pantec raised $19M in two private financing rounds with StemCell Holding AG as lead investor |
Poxel SA |
Lyon, France |
7/9 |
€16 ($20.2) |
Poxel raised $20.2M in a Series A round led by Edmond de Rothschild Investment Partners and including the InnoBio fund, which is managed by CDC Entreprises and Credit Agricole Private Equity |
Reata Pharmaceuticals Inc. |
Irving, Texas |
7/12 |
$78 |
Reata added $78M in a Series G round led by CPMG Inc. and Novo A/S |
Tethys Bioscience Inc. |
Emeryville, Calif. |
7/22 |
$33 |
Tethys raised $33M, of which $23M was venture funding and $10M was a working capital loan; investors were Greenspring Associates Inc., Paul Capital Investments and current investors; the loan was provided by Oxford Finance Corp. and Silicon Valley Bank |
Trevena Inc. |
King of Prussia, Pa. |
7/14 |
$35 |
Trevena raised $35M in a Series B round led by New Enterprise Associates and Polaris Venture Partners; it also included Alta Partners, Healthcare Ventures and Yasuda Economic Development Corp. |
Vicept Therapeutics Inc. |
Malvern, Pa. |
7/1 |
$16 |
Vicept secured $10M to complete a total $16M Series A led by Vivo Ventures, Sofinnova Ventures and Fidelity Biosciences |
Zogenix Inc. |
San Diego |
7/14 |
$40 |
Zogenix secured a $35M debt facility led by Oxford Finance Corp., which included Silicon Valley Bank; the facility consists of a $25M term loan and a $10M revolving line of credit; in addition to the $25M loan, the company is now getting a $15M investment from Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, Abingworth Management and Chicago Growth Partners |
|
Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International. The date indicated refers to the BioWorld Today issue in which the news item can be found. ND = Not disclosed. |
